<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102559">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769352</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00074523</org_study_id>
    <nct_id>NCT01769352</nct_id>
  </id_info>
  <brief_title>Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)</brief_title>
  <acronym>TEMPEST</acronym>
  <official_title>Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the change in visual acuity of patients with post
      surgical cystoid macular edema who will be treated with two different regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the mean change in BCVA over 12 weeks of Prednisolone Acetate 1% q1h (every hour) WA
      (While Awake) + Ketorolac 0.5% qid (four times a day) versus Prednisolone Acetate qid +
      Ketorolac qid for post surgical cystoid macular edema.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in BCVA</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Post-surgical Cystoid Macular Edema (PSCME)</condition>
  <arm_group>
    <arm_group_label>PredA q1h WA + Kelac qid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PredA qid + Kelac qid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PredA + Kelac</intervention_name>
    <description>At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.</description>
    <arm_group_label>PredA q1h WA + Kelac qid</arm_group_label>
    <arm_group_label>PredA qid + Kelac qid</arm_group_label>
    <other_name>Acular, Acuvail</other_name>
    <other_name>Pred Forte, Omnipred, Pred Mild</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than or equal to 18 years

          -  Diagnosis of PSCME in study eye confirmed by FA showing leakage from retinal vessels
             resulting in pooling of dye in the fovea and Spectralis SD-OCT showing intraretinal
             fluid in or around the fovea.

          -  BCVA score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using
             the ETDRS protocol at a distance of 4 meters).

          -  In the opinion of the investigator, decreased vision in the study eye is due to
             foveal thickening from PSCME and not to any other reason.

        Exclusion Criteria:

          -  Any patient who has other retinal diseases known to cause macular edema (choroidal
             neovascularization, vein occlusion, diabetic macular edema in the study eye).
             Patients with nonexudative Age Related Macular Degeneration (ARMD) or
             non-proliferative diabetic retinopathy without macular edema can be included in the
             study.

          -  Other reason for decreased visual acuity (such as amblyopia, foveal atrophy, optic
             atrophy).

          -  Pre-existing diagnosis of glaucoma in the study eye

          -  Inability to comply with study or follow up procedures

          -  Pregnancy (Women of child bearing age will be asked to take a urine pregnancy test
             prior to enrolling in the study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 19, 2016</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Peter A Campochiaro, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cystoid macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
